-
Something wrong with this record ?
Solid Forms of Tenofovir Disoproxil Fumarate, Their Mutual Conversion, and Stabilization of Form I in Formulation
V. Sládková, O. Dammer, B. Kratochvíl,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- X-Ray Diffraction methods MeSH
- Hydrogen-Ion Concentration MeSH
- Anti-HIV Agents chemistry metabolism MeSH
- Excipients chemistry metabolism MeSH
- Drug Compounding methods MeSH
- Drug Stability MeSH
- Tenofovir chemistry metabolism MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Tenofovir disoproxil fumarate (TDF, form I) is an orally delivered pharmaceutical salt used for the treatment of HIV and chronic hepatitis, which acts as an inhibitor of nucleotide reverse transcriptase. There are many solid forms of TDF described in the literature; 2 of them were identified in the drug products: form I and form A. It seems that during formulation, the active pharmaceutical ingredient undergoes partial to total conversion of TDF form I to TDF form A. The goals of this study were to investigate when and why did the conversion occur and whether the conversion could be avoided and how. The influence of pH and possible interaction with excipients were studied. The conditions enabling using wet granulation in technology while preventing the undesired conversion were found. The stabilization was achieved either by replacement of used disintegrants or by acid addition to the current composition of formulation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017097
- 003
- CZ-PrNML
- 005
- 20230712135335.0
- 007
- ta
- 008
- 180515s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.xphs.2016.07.002 $2 doi
- 035 __
- $a (PubMed)27522525
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Sládková, Veronika $u Department of Solid State Chemistry, University of Chemistry and Technology Prague, Prague 6, Czech Republic 16628; Solid State Department, Zentiva, k.s., Prague 10, Czech Republic 10237. Electronic address: sladkovv@vscht.cz.
- 245 10
- $a Solid Forms of Tenofovir Disoproxil Fumarate, Their Mutual Conversion, and Stabilization of Form I in Formulation / $c V. Sládková, O. Dammer, B. Kratochvíl,
- 520 9_
- $a Tenofovir disoproxil fumarate (TDF, form I) is an orally delivered pharmaceutical salt used for the treatment of HIV and chronic hepatitis, which acts as an inhibitor of nucleotide reverse transcriptase. There are many solid forms of TDF described in the literature; 2 of them were identified in the drug products: form I and form A. It seems that during formulation, the active pharmaceutical ingredient undergoes partial to total conversion of TDF form I to TDF form A. The goals of this study were to investigate when and why did the conversion occur and whether the conversion could be avoided and how. The influence of pH and possible interaction with excipients were studied. The conditions enabling using wet granulation in technology while preventing the undesired conversion were found. The stabilization was achieved either by replacement of used disintegrants or by acid addition to the current composition of formulation.
- 650 _2
- $a látky proti HIV $x chemie $x metabolismus $7 D019380
- 650 _2
- $a příprava léků $x metody $7 D004339
- 650 _2
- $a stabilita léku $7 D004355
- 650 _2
- $a pomocné látky $x chemie $x metabolismus $7 D005079
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a tenofovir $x chemie $x metabolismus $7 D000068698
- 650 _2
- $a difrakce rentgenového záření $x metody $7 D014961
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dammer, Ondřej $u Solid State Department, Zentiva, k.s., Prague 10, Czech Republic 10237. $7 xx0303489
- 700 1_
- $a Kratochvíl, Bohumil $u Department of Solid State Chemistry, University of Chemistry and Technology Prague, Prague 6, Czech Republic 16628.
- 773 0_
- $w MED00002895 $t Journal of pharmaceutical sciences $x 1520-6017 $g Roč. 105, č. 10 (2016), s. 3136-3142
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27522525 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20230712135337 $b ABA008
- 999 __
- $a ok $b bmc $g 1300721 $s 1013937
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 105 $c 10 $d 3136-3142 $e 20160810 $i 1520-6017 $m Journal of pharmaceutical sciences $n J Pharm Sci $x MED00002895
- LZP __
- $a Pubmed-20180515
